Table 1.

Comparison of domains reported as being important to patients with PMR. Outcomes measured in 35 clinical trials and longitudinal observational studies9, grouped according to the OMERACT Filter 2.0 Framework. Adapted from Duarte, et al. J Rheumatol 2015;42:2503–11; with permission9.

Core AreaDomainInstrument Used in Published StudiesNo. Studies of PMR Reporting Data on This Domain
Pathophysiological manifestationsLaboratory markers of systemic inflammationESR, CRP, IL-6, fibrinogen30
Elevation of upper limbsPart of composite disease activity score5
Ability to carry out physical function testsGrip strength, chair stand, 10-m walk1
UltrasonographySynovitis, bursitis in shoulder and hip regions4
Physician’s globalVAS, NRS14
Life impactPainVAS, NRS17
Morning stiffnessDuration (min), grade, severity (VAS)26
FatigueVAS1
Sleep disturbanceNot reported0
Patient’s globalVAS, NRS9
Physical functioning (in daily living)HAQ9
Anxiety, depressionPart of SF-362
Health-related quality of lifeSF-36, VAS3
DeathMortalityDeath registries, patient files1
Resource useNot reportedNot reported0
Adverse eventsAdverse effects of medicationStandard methods for clinical trials14
  • Bold face indicates highlighted in initial patient consultations11. PMR: polymyalgia rheumatic; OMERACT: Outcome Measures in Rheumatology; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IL-6: interleukin 6; VAS, visual analog scale; NRS: numerical rating scale; HAQ: Health Assessment Questionnaire; SF-36: Medical Outcomes Study Short Form-36.